key: cord-0879333-o2iny77o
authors: Yin, Wanchao; Luan, Xiaodong; Li, Zhihai; Xie, Yuanchao; Zhou, Ziwei; Liu, Jia; Gao, Minqi; Wang, Xiaoxi; Zhou, Fulai; Wang, Qingxia; Wang, Qingxing; Shen, Dandan; Zhang, Yan; Tian, Guanghui; Aisa, Haji A.; Hu, Tianwen; Wei, Daibao; Jiang, Yi; Xiao, Gengfu; Jiang, Hualiang; Zhang, Leike; Yu, Xuekui; Shen, Jingshan; Zhang, Shuyang; Xu, H. Eric
title: Structural basis for repurpose and design of nucleoside drugs for treating COVID-19
date: 2020-11-02
journal: bioRxiv
DOI: 10.1101/2020.11.01.363812
sha: 4f927f77c91b19faa9a7fd382202c8678719f978
doc_id: 879333
cord_uid: o2iny77o

SARS-CoV-2 has caused a global pandemic of COVID-19 that urgently needs an effective treatment. Nucleoside analog drugs including favipiravir have been repurposed for COVID-19 despite of unclear mechanism of their inhibition of the viral RNA polymerase (RdRp). Here we report the cryo-EM structures of the viral RdRp in complex with favipiravir and two other nucleoside inhibitor drugs ribavirin and penciclovir. Ribavirin and the ribosylated form of favipiravir share a similar ribose scaffold that is distinct from penciclovir. However, the structures reveal that all three inhibitors are covalently linked to the primer strand in a monophosphate form despite the different chemical scaffolds between favipiravir and penciclovir. Surprisingly, the base moieties of these inhibitors can form mismatched pairs with the template strand. Moreover, in view of the clinical disadvantages of remdesivir mainly associated with its prodrug form, we designed several orally-available remdesivir parent nucleoside derivatives, including VV16 that showed 5-fold more potent than remdesivir in inhibition of viral replication. Together, these results demonstrate an unexpected promiscuity of the viral RNA polymerase and provide a basis for repurpose and design of nucleotide analog drugs for COVID-19. One Sentence Summary Cryo-EM structures of the RNA polymerase of SARS-CoV-2 reveals the basis for repurposing of old nucleotide drugs to treat COVID-19.

# Co-corresponding authors: H. Eric Xu, eric.xu@simm.ac.cn; or Shuyang Zhang (shuyangzhang103@nrdrs.org ); or Jingshan Shen (shenjingshan@simm.ac.cn), or Xuekui Yu (xkyu@simm.ac.cn ); or Leike Zhang (zhangleike@wh.iov.cn ) One Sentence Summary: Cryo-EM structures of the RNA polymerase of SARS-CoV-2 reveals the basis for repurposing of old nucleotide drugs to treat COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the pandemic of COVID-19, has continued to infect many people across the world (1, 2). SARS-CoV-2 is related to the highly pathogenic beta-coronaviruses that include SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) (3) . These viruses are positive-sense, singlestranded RNA viruses and their infections could lead to severe acute respiratory syndrome, which could result in loss of lung function and death. Among these related coronaviruses, SARS-CoV-2 has much higher activity to spread among humans, resulting in a global scale of health crisis, which still needs an effective treatment. Drug development usually requires a decade long of effort and it is unfit for current medical crisis. Repurpose of existing drugs that bypass regular preclinical and clinical research is of tremendous medical importance to combat the pandemics of COVID-19.

The viral RNA-dependent RNA polymerase (RdRp) is essential for viruses to replicate and has served as a major drug target for antiviral therapy. Numerous nucleotide analogs, including favipiravir (4, 5) , ribavirin (6, 7) , and penciclovir (8) , have been developed to target the polymerase of different viruses such as influenza virus, hepatitis C virus (HCV), and Zika virus (ZIKV). The recent structure of the SARS-CoV-2 RdRp in complex with RNA substrate and had a relatively low processivity on a poly-G template when compared to poly-U and poly-A templates ( Fig.1B-1D ).

In parallel, the triphosphate forms of ribavirin (RBV-TP) and penciclovir (PEV-TP) were also able to inhibit the RdRp primer extension activity. Surprisingly, RBV-TP exerted the most potent inhibition on the poly-G template (Fig.1C) , in contrast to the proposed model of ribavirin as a guanosine analog(18). PEV-TP showed comparable inhibition on poly-U and poly-C templates ( Fig.1D) , suggesting that guanine base can form mismatched pairing with pyrimidine base. The potency of PEV-TP is in the same range of FAV-TP and RBV-TP. To corroborate these biochemical data, we tested the ability of favipiravir, ribavirin, and penciclovir to inhibit viral replication in Vero E6 cells, in which the nucleotide prodrugs can be metabolized into the active triphosphate forms. In these cell-based assays, favipiravir, ribavirin, and penciclovir exhibited similar antiviral activity ( Fig. 1E) with EC50 values of 96, 40, and 12 μM, respectively. In comparison, remdesivir has an EC50 value of 1.57 μM in cell-based anti-viral assays (Fig. 1E) , suggesting remdesivir is more potent than favipiravir, ribavirin, and penciclovir. However, remdesivir has higher cell toxicity (CC50=264 μM) than favipiravir, ribavirin, and penciclovir, all three of them have CC50 values higher than 1000 μM (Fig. 1E ).

To determine the structural basis of RdRp inhibition, we prepared the purified nsp12-7-8 complex (fig. S1A-1B) in the presence of an RNA template-primer duplex (fig. S1D) and the triphosphate forms of nucleotide inhibitors, which were added in more than 300 fold of molar excess to the RdRp to obtain a stable and completely inhibited complex for cryo-EM studies.

For the FAV-bound RdRp complex, we collected over 3,209 micrograph movies of more than 5.303 million particle projections. Of these, 116,511 particles were used to yield a density map of 2.7 Å resolution ( fig. S4 ). For the RBV-bound RdRp complex, we collected over 4,297 micrograph movies of more than 4.974 million particle projections. Of these, 196,511 particles were used to yield a density map of 2.97 Å resolution ( fig. S5 ). For the PEV-bound RdRp complex, we collected over 3,913 micrograph movies of more than 5.240 million particle projections. Of these, 142,242 particles were used to yield a density map of 2.6 Å resolution for the overall conformation, and 139,773 particles were used to yield a density map of 2. which is similar to the recent structures of RdRp in a transcribing conformation (10, 19, 20) . to the previous remdesivir-bound structure (9) .

In addition to the covalent link of the monophosphate forms of the nucleotide inhibitors to the primer strand, the binding poses of these nucleotide inhibitors are stabilized by base pairing and stacking interactions with the double strand RNA, as well as interactions with protein residues at the catalytic center ( Fig. 2G-I) . For the FAV-bound RdRp complex, FAV-MP mimics an adenosine analog to form two hydrogen bonds with +1 uridine from the template strand (Fig.   2G ). In addition, the FAV base forms hydrogen bond with K545 and S682 of nsp12 whereas the phosphor-ribose makes interactions with D623, N691 and the catalytic D760 (Fig. 2G ). For the RBV-bound RdRp complex, RBV-MP mimics a guanosine analog to form two hydrogen bonds with +1 cytosine from the template strand (Fig. 2H ). In addition, the RBV base forms hydrogen bond with K545 and S682 of nsp12, and stacking interaction with R555, whereas the phosphorribose makes interactions with D623, N691 and the catalytic D760 , (Fig. 2H ). For the PEVbound RdRp complex, the guanosine from PEV-MP forms two hydrogen bonds with +1 mismatched uridine from the template strand (Fig. 2I ). In addition, the guanosine base forms hydrogen bonds with S682 main chain CO of nsp12 whereas the phosphate backbone makes interactions with the catalytic D760 (Fig. 2I ). The hydroxyl of penciclovir forms additional hydrogen bonds the side chain of D623 (Fig. 2I ).

RNA replication by the viral RdRp involves at least two critical conformation states (10, 21) , the pre-translocated conformation state in which the newly incorporated nucleotide is the +1 position within the catalytic site and the post-translocated conformation state in which the newly incorporated nucleotide is translocated into the -1 position, which will empty the +1 position to allow a new incoming nucleotide into the catalytic center. Currently the structures of SARS-CoV-2 RdRp have been solved with four different nucleotide inhibitors, FAV, RBV, PEV, and RDV. Comparison of these inhibitor-bound structures with the RdRp structure with native RNA (10, 19, 20) reveals that these nucleotide inhibitors are located at +1 position in the pretranslocated conformation state despite that FAV-TP, RBV-TP, and PEV-TP were added in vast excess during the complex formation (Fig. 3A) . The positions of the base analogs, ribose and phosphate backbone of FAV-MP, RBV-MP, and RDV-MP are nearly overlapped with each other (Fig. 3A) . PEV-MP does not have a ribose but its guanine base and phosphate backbone are also overlapped with FAV-MP and RBV-MP. The concentrations of the triphosphate form of these nucleotide inhibitors used in complex assembly were at 1 mM, which are comparable to the in vivo concentrations of natural NTP, thus it is surprised to observed that only a single base of nucleotide inhibitor was added to the 3' end of the primer strand despite the availability of the 3' OH from the nucleotide inhibitors to couple with the incoming 5' triphosphate of the next inhibitor. Therefore, these inhibitors act like immediate chain terminators in the experimental conditions we used. Our structures are different from a recent structure of the RdRp in complex with RDV-TP in the presence of excess amount of GTP ( Fig. 3B and fig. S12A ), in which RDV-MP is at the -1 position and only one GMP at the +1 position despite the +2 position is a cytosine in the template strand, which is compatible with an incoming GTP. Thus, this inhibitor-RdRp complex is also stalled at the pre-translocated conformation despite an excess amount of native NTP for primer extension. This is in contrast to the RdRp RNA complex in the presence of only natural NTP (Fig. 3C -3E and fig. S12B-S12D), which structure reveals a posttranslocated conformation, readily to adopted a new nucleotide for primer extension. Despite these structural differences, these nucleotide inhibitors seem to act through a common mechanism by stalling the RdRp complex at the stage of pre-translocated conformation.

Among the above four nucleotide analog drugs, remdesivir is the first one that has been approved by FDA for COVID-19 through vein injection. This is probably that remdesivir has the most potent EC50 against SARS-CoV-2 in cell-based assays(22) (EC50 of remdesivir is~1-2 µM vs 10-100 µM for FAV, RBV, and PEV, Fig. 1E ). However, remdesivir has disadvantages of difficulties in chemical synthesis and obligatory intravenous (IV) injection that requires hospital settings. In addition, pharmacokinetics of remdesivir shows that it is rapidly metabolized into its nucleotide form and it is highly enriched in liver that can cause hepatotoxicity(23, 24). Thus, it has been argued that parent nucleoside of remdesivir should have advantage for COVID-19 treatment(25). Indeed, cell-based inhibition assays of viral replication reveals that the parent nucleoside is about 3-fold more potent than remdesivir ( Fig. 1E and Fig. 4A -B)(22). The deuterated analog bearing a deuterium atom at the C5 position of the base moiety further improve oral bioavailability ( Fig. 4A and 4C ). Prodrug modification of the deuterated nucleoside that is esterified with isobutyric acid further improved the viral inhibition potency ( Fig. 4A and   4B ). Together, the final modified compound X3 has an overall 5-fold potency improvement in inhibiting the viral replication over the original remdesivir ( Fig. 4A and 4B ).

More importantly, compound X3 can be delivered via oral route with excellent bioavailability up to 56% (X3, Fig. 4C ) and good retention time. In contrast to liver-enriched remdesivir, X3 achieves a well distribution of the nucleoside and nucleotide metabolite in the blood plasma as well as in many critical organs including lung that is vulnerable to SARS-CoV-2 infection, suggesting that X3 is a good drug candidate for treating COVID-19. A pilot experiment of inhibition of SARS-CoV-2 in mice transfected with human ACE2 demonstrated that mice treated with an acid salt form of X3 (development code: VV116) had 50-fold lower in viral load than the untreated mice (Fig S13A-C) . The lung tissues of untreated mice were positive in immune staining of viral antigen of N protein but were negative in lung tissues from VV116-treated mice ( Fig S13D) . Together, these initial data demonstrated the antiviral efficacy of VV116 in the mouse model transfected with human ACE2.

The ongoing COVID-19 pandemic by no-stop infections of SARS-CoV-2 has caused a global health crisis that urgently request for an effective treatment. Because drug development normally takes a decade long of preclinical and clinical research, which is clearly unfit for current medical emergency. Drug repurposing that could bypass regular preclinical and clinical research is of critical importance in the current situation to combat the pandemics of COVID-19. In this paper, we demonstrated three existing drugs, favipiravir, ribavirin, and penciclovir, all nucleotide analogs, are inhibitors of the SARS-CoV-2 RdRp, an essential enzyme for the viral replication.

We have further determined the structures of these three nucleotide analog drugs in complex with the SARS-CoC-2 RdRp and a template-primer RNA. Despite that penciclovir does not have a ribose scaffold that is shared by favipiravir and ribavirin, all nucleotide inhibitors are covalently linked to the primer strand in a monophosphate form, in which the RdRp RNA template-primer complex is stalled at the pre-translocated conformation state, revealing a common RdRpinhibition mechanism that is also shared by the remdesivir bound RdRp complex. In addition, we discovered a terminal nucleotide transferase activity of the SARS-CoV-2 RdRp, which can add an additional nucleotide to the primer strand beyond the template end. The SARS-CoV-2 RdRp also display a remarkable promiscuity with respect to the incorporation of nucleotides that are unmatched with bases from the template strand. Based on these structures and previous remdesivir-bound structures, we designed several orally-available remdesivir derivatives that showed potent inhibition of viral replication in cell-based assays and animal models of SARS-CoV-2 infections. Our results provide a rational basis for repurpose of favipiravir, ribavirin, and penciclovir for treating COVID-19. The structures also provide a set of templates for designing the next generation of orally-available nucleotide analog drugs for COVID-19.

Microbiology, (2020 

The RdRp complex was prepared according to the same method reported(17) as described below. The full-length gene of the SARS-CoV-2 nsp12(residues 1-932) was chemically 168,937 selected particles were subjected to rounds of 3D refinement, CTF refinement, Baysian particle polishing, and finally generating a final reconstruction at a global resolution of 2.95 Å.

Since negligible structural difference at the catalytic active site was present between extended and non-extended forms, the two particle sets were combined to determine a structure with higher resolution at the core part of the polymerase. After a round of focused alignment with a mask including RNA and nsp12, 142,242 particles were finally selected and produced a final overall structure of Penciclovir-TP complex at a resolution of 2.60 Å by the same refinement procedures as above described. Table S1 . Structural figures were prepared in Chimera or Chimerax(36).

The corresponding template-primer pair RNA strands were mixed at equal molar ratio in annealing buffer (10 mM Tris-HCl, pH 8.0, 25 mM NaCl and 2.5 mM EDTA). To anneal the RNA duplex, both oligonucleotides were denatured by heating to 94°C for 5 min and then slowly cooled to room temperature. For the self-priming RNA2 used in the RBV bound RdRp complex, the RNA2 itself was denatured by heating to 94°C for 5 min and then slowly cooled to room temperature.

The 

For the synthesis of FAV-TP, The protective group was reacted at -2℃ under perchloric acid.

1,2,3,5-tetraacetylribose reacted with favipiravir at 0℃ for 24 hours, then sodium methoxide was added for deprotection, and quickly stirred for 5 minutes. And separated, synthesis intermediate.

Favipiravir (100 mg) and trimethyl phosphate (1 mL) were added to a 100 mL three-necked flask, and replaced three times under vacuum-nitrogen conditions. Cool down to 0~5℃ in an ice-salt bath, and slowly add phosphorus oxychloride (30uL). The reaction system was stirred at 0°C for about 3 hours. Then add n-trioctylamine (190 mg), n-tributylamine pyrophosphate (290 mg) in N, N-dimethylformamide (3 mL) suspension. The reaction system was stirred at 4°C for 12 hours.

The reaction solution was added with dichloromethane (25 mL) and stirred for 30 minutes, then filtered. After the filter cake was dissolved in water, the pH was adjusted to 7 with an aqueous sodium bicarbonate solution. The aqueous phase was extracted with methyl tert-butyl ether (5 mL*2) and concentrated at low temperature to remove water. The obtained residue was prepared and purified by HPLC and then lyophilized to obtain pure product.

For the synthesis of RBV-TP, Ribavirin (100 mg) and trimethyl phosphate (1 mL) were added to a 100 mL three-necked flask, and replaced three times under vacuum-nitrogen conditions. Cool down to 0~5℃ in an ice-salt bath, and slowly add phosphorus oxychloride (30uL). The reaction system was stirred at 0°C for about 3 hours. Then add n-trioctylamine (190 mg), n-tributylamine pyrophosphate (290 mg) in N,N-dimethylformamide (3 mL) suspension. The reaction system was stirred at 4°C for 12 hours. The reaction solution was added with dichloromethane (25 mL) and stirred for 30 minutes, then filtered. After the filter cake was dissolved in water, the pH was adjusted to 7 with an aqueous sodium bicarbonate solution. The aqueous phase was extracted with methyl tert-butyl ether (5 mL*2) and concentrated at low temperature to remove water. The obtained residue was prepared and purified by HPLC and then lyophilized to obtain pure product.

For the synthesis of PEV-TP, add penciclovir (100 mg) and trimethyl phosphate (1 mL) to a 100 mL three-necked flask, and replace with vacuum-nitrogen three times. Cool down to 0~5℃ in an ice-salt bath, and slowly add phosphorus oxychloride (30uL). The reaction system was stirred at 0°C for 36 hours and quenched to purify the pure penciclovir monophosphate required for one side. Then add n-trioctylamine (190 mg), n-tributylamine pyrophosphate (290 mg) in N,Ndimethylformamide (3 mL) suspension. The reaction system was stirred at 0°C for 12 hours.

The reaction solution was added with dichloromethane (25 mL) and stirred for 30 minutes, then filtered. After the filter cake was dissolved in water, the pH was adjusted to 7 with sodium bicarbonate aqueous solution. The aqueous phase was extracted with methyl tert-butyl ether (5 mL*2) and concentrated at low temperature to remove water. The obtained residue was prepared by HPLC and lyophilized to obtain pure product.

The PK studies were conducted at Suzhou HQ Bioscience Co., Ltd. The animals (N = 3 for SD rats) were fasted for 12 h before the administration of tested compounds. For PK studies in rats, 

Sixteen male CD-1 mice were randomly divided into four groups (n = 4, each). All mice were 

African green monkey kidney Vero E6 cells (ATCC-1586) were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin antibiotics. Cells were kept at 37°C in a 5% CO2 atmosphere. The strain (nCoV-2019BetaCoV/Wuhan/WIV04/2019) of SARS-CoV-2, which was isolated from a clinical patient, was obtained from National Virus Resource Center. The virus strain was propagated in Vero E6 cells.

In our study, Vero E6 cells were pre-seeded to 48-well plates ( For cytotoxicity measurement, Vero E6 cells were added to a 96-well plate (20,000 cells/well), and added with medium containing gradient concentration of nucleotide analogs at 100 μL/well next day. The 50% cytotoxicity of VV116 was determined after 24 h using the CCK8 assay kit, and CC50 of nucleotide analogs was calculated with Graphpad Prism software 8.0.

The BALB/c mice were bred and maintained in specific pathogen free (SPF) environment at the 

Compound 

To a solution of compound X1 (0.58 g, 2.0 mmol) in DMF (10 mL) was added N,Ndimethylformamide dimethyl acetal (1.43 g, 12.0 mmol) at room temperature. The mixture was stirred at 60 o C for 2 h, then cooled to room temperature, and an equivalent volume of methanol was added. The solvent was evaporated under vacuum to give an oily residue which was treated with isopropyl alcohol. The resulting precipitate was collected by filtration and dried to

give compound 3-1 as an off-white solid (0.55 g, 80% yield).

Compound 3-1 (0.37 g, 1.0 mmol), triethylamine (0.81 g, 8.0 mmol) and DMAP (0.37 g, 3.0 mmol) were suspended in methylene chloride (10 mL), and to this solution was slowly added isobutyryl chloride (0.43 g, 4.0 mmol) at room temperature. The mixture was stirred until the starting material completely disappeared. The solvent was removed under vacuum, and the residue was partitioned between water and ethyl acetate. The organic layer was separated, washed successively with 1M hydrochloric acid, saturated sodium bicarbonate and brine, then dried over Na2SO4, and evaporated to give the crude product 3-2 as an oil, which was taken directly to the following step without further purification. 

CGAUACACUCUAAUUCAAUAAAAAAAAAAA 5' 

Severe acute respiratory syndrome-related coronavirus: The species and its viruses -a statement of the Coronavirus Study Group. bioRxiv

An interactive web-based dashboard to track COVID-19 in real time

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Influenza virus polymerase inhibitors in clinical development

Mechanism of action of ribavirin in the treatment of chronic hepatitis C

Use of Ribavirin for Hepatitis C Treatment in the Modern Directacting Antiviral Era

Selected nucleos(t)ide-based prescribed drugs and their multi-target activity

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Structural basis for RNA replication by the SARS-CoV-2 polymerase

Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

Favipiravir: A new and emerging antiviral option in COVID-19

Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. bioRxiv : the preprint server for biology

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Favipiravir: A new and emerging antiviral option in COVID-19

Characteristics of SARS-CoV-2 and COVID-19

57 mmol) was added to anhydrous tetrahydrofuran (20 mL) and deuteroxide (2 mL), and then the solvent was removed in vacuum. The procedure was repeated, followed by addition of tetrahydrofuran (20 mL) and deuteroxide (2 mL) again. To this solution were added 1,1'-bis(diphenylphosphino)ferrocene-palladium

14 mmol) was added in portion within 30 min. The mixture continued to be stirred at room temperature until the starting material disappeared completely. Then, the reaction was quenched with saturated NH4Cl solution, and extracted with ethyl acetate. The organic phase was washed with brine, dried over Na2SO4, and concentrated. The residue was purified by chromatography on silica gel to give compound 1-3 with a deuterium content

Debenzylation of compound 1-3 (0.56 g, 1.0 mmol) with 1M BCl3 dichloromethane solution

381) to afford compound X1 as a white solid (0.15 g, yield 53%). 1 H NMR (500 MHz, DMSO-d6) δ 8.01 -7.79 (m, 3H), 6.88 (s, 1H)